Insulin Glargine and Lixisenatide vs Insulin Aspart — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Insulin Analog

Insulin Glargine and Lixisenatide

Brand: Soliqua 100/33

First FDA approval: 2016-11-21

Insulin Analog

Insulin Aspart

Brand: .Insulin Aspart Protamine and Insulin Aspart

First FDA approval: 2001-08-27

Lowest NADACAcquisition cost floor across all NDCs

$57.05Per unit

$6.94Per unit

Average NADACAcross all dosage forms and strengths

$57.05Up to $57.05

$8.12Up to $8.96

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

—Full year

$704.9MFull year

Part D claims (CY24)Total fills, all strengths

—— beneficiaries

3.4M1.3M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

—Per claim, all NDCs

$205Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

92Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

4Limited friction

10Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

DiscontinuedSee drug profile

Generic availableFDA Orange Book

NoBrand-only